Mobility is great. Hypermobility? Less great. In the joints, hypermobility leads to musculoskeletal pain – and often times, lots of it. A recent review in the Journal of Pain Research outlined several of the challenges in treating generalized joint hypermobility (GJH) and found many difficult questions and few easy answers.
Study results suggest that longer exposure to methotrexate and other disease-modifying anti-rheumatic drugs within the first year of diagnosis is associated with a significantly longer time to joint replacement surgery.